Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow registered in Nevada 17 years. The positive outcome of the payer analysis is maybe what closed the deal then. Hopefully your right and we hear it from HQ.
Also looking for a buyout.
By my account 10q is not due till next week. Military symposium highlighting Brilacidin next week. He still has a few million in the bank and hasn't it been incessantly posted that paycheck Leo isn't going anywhere.
My bet is before failure happens a reverse split would take place to get OM funded.
B has shown to be safe and effective in three separate phase2 trials.
It does not say will be part of a break out discussion (but likely will be) it states will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2)
As pointed out in the poster yes there is a break out session and likely after the presentation in my opinion.
If the wording was "may" then I would say less likely but it clearly says "will". In the end if IPIX gets funding then we know for sure, if not then it was misleading.
Looks like the $20M offering announced on the run up killed momentum. They are shooting for a pivotal phase3. AVXL has a big lead if news is good.
I agree. The wording is clear.
See what happens with it.
For next week--Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium September 12-15 2022
Poster-- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases
Broad-Spectrum countermeasure is exciting.-- "will be" a statement as is going to be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases
The poster statement screams government funding.
So funny... Clearly everyone's invested.
Leo has let this slip before. Hopefully he's just busy attaining OM funding.
I don't get caught up in the hyperbole stuff. The payer analysis was good to see though. Hopefully this leads us to green pastures:) Good luck to you. I see we have a couple of the same interests.
Yes I get your point we are in the middle of support and resistance. Market is waiting to see if we get funding I suppose.
Over these many years NNVC has yet to be in one clinical trial but is currently trading at $2.39.
As a reminder B has been in three successful phase2 trials. I figure since Leo has yet to announce a need for a reverse split this gives me more confidence in funding. We'll see.
-B has shown the ability to help against oral mucositis a current unmet need.
-Ongoing NIH testing showing B as a possible broad spectrum anti-viral.
-As an antibiotic Brilacidin has also proven to heal ABSSSI (infections) in a single dose.
-Last but not least B can cure ulcerative proctitis/sigmoiditis/ If proven the thought is B could be used in pill form to treat ulcerative colitis of the complete colon. B has a lot going for it in a time of great need.
As a whole I would say B is very undervalued.
Yes it should be stickied. It's a posters breakdown of much promising Brilacidin work. These type things use to get stickied.
Why the criticism. It may just end up being something big for that someone.
Very nice work. Thank you!
Or that Redesiver failed it's first trial but with more testing went on to be the standard of care. Through the NIH Brilacidin is also getting further testing. Likely even much further.
March release reported: The Company has also been notified by Alfasigma, its licensing partner, of their intent to initiate this year Phase 2 testing of Brilacidin in Ulcerative Proctitis/Proctosigmoiditis.
Since the covid-19 shut down things are starting to get back on track.
Likely not DeGrado at the presentation. More likely university scientist directly involved possibly with DeGrado input in creating the poster and for QandA. We'll see.
Release says it's a POSTER presentation with a breakout session. Who will be there to answer the discovery and MOA questions, a job for Dr DeGrado but it's not a lecture.
What fake news? I see posters who are bullish and those who are bearish. I for one like the fact that B is still being tested by the NIH for it's anti-viral properties and that a payer analysis was completed.
NIH is paying for research to test Brilacidins anti-viral potential. Latest testing is on the Monkeypox virus.
"Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin)".
Go killer B, too bad coronavirus.
Up 300% since the lows. The front side of that chart would have shown IPIX at a few dimes to a climb of $4.97. Fantastic run.
I think that spike to .06 was a shot across the bow. Shaping up to buy or chase. The right news and flippers may just find themselves left out.
Not even close lemon.
Yes RBL's are still doing research one reported 6/23 is Rutgers University where it was reported that Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants.
The last report in the 8/5 press release did not disclose the lab but stated NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin’s Treatment Potential Against Monkeypox.
Lab studies are in the releases. I don't know who the point person will be.
I don't think some are happy about it. Go IPIX
Yes we are seeing support. So we have NIH still funding our anti-viral testing and seeing positive results. Go killer B
It's hard telling what those sick poor folks had in their bodies at the time they were admitted in the trial.
These days everything is behind. It's not hard to forecast.
Yeah right ss's point trumps the press release. Meanwhile NIH/NIAID is evaluating Brilacidin as a broad spectrum anti-virus.
"To say that Brilacidin "has been proven to have antiviral activity, inhibiting the SARS-CoV-2 virus in Vero African green monkey kidney cells and Calu-3 human lung epithelial cells, and showing a synergistic inhibitory activity in combination with the antiviral remdesivir" and then to fail to note that "Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29",
"Obviously you are entitled to describe the paper as "news" just as I am free to describe it as "deceptive" but only one of us is correct. Would you like me to go over the facts again?
Then again you LR failed to say these facts- "certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03).
And now we know the NIH/NIAID is evaluating Brilacidin as a possible treatment against Monkeypox. This might be number 23 or is it over 25 viruses that B is being tested against. We know from reports the NIH has researched B against a plethora of different nasty viruses where it has shown broad spectrum anti-viral activity. An easy take away is B keeps showing positive anti-viral results and the government keeps allocating funds toward it.
Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell
https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.27616
Don't forget IPIX has been invited to the 2022 Military Health System Research Symposium (MHSRS), Sept 12-15
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
The criteria is being negative to the cause like all the others.
Just One Sample off the top - Btw share price would had doubled for the purchaser.
Lemoncat
Thursday, April 21, 2022 9:51:20 PM
Re: PJ007 post# 389394
Post# of 392162
Well. In my opinion if one is dumb enough to attempt to buy 100k shares of IPIX today, they might have been dumb enough to click sell instead of buy.
Not you. Just a general thought about buying/selling IPIX.
Remdesiver failed it's first clinical trial miserably but yet went on to be a standard of care for covid-19. B needs another chance especially with all this new positive anti-viral evidence that has come to light.
Symposium Poster sure makes it sound like funding is likely coming.
Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
B proving out to be a Broad Spectrum Anti-viral. Killer B.
2022 Military Health System Research Symposium (MHSRS), Sept 12-15
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
Clearly the market used the progress to make money. Regressed after a steep climb to .06. Likely see more of it.